SANUWAVE Health, Inc. (NASDAQ: SNWV) will host a live earnings call on Friday, March 27, 2026, at 8:30 AM ET to present its Q4 and full‑year 2025 financial results. The call will be available via toll‑free dial‑in numbers and a webcast link, and a replay will be posted on the company’s investor‑relations website through April 10, 2026.
The company has already released preliminary guidance for the quarter and the year. For Q4 2025, SANUWAVE expects revenue between $13.0 million and $13.4 million, a 29‑30% year‑over‑year increase that would set a new quarterly record. Full‑year 2025 revenue is projected to fall between $44.3 million and $44.4 million, up 36% from 2024 and also a record for the company. These figures are consistent with the guidance issued in the Q3 2025 earnings release and reflect continued demand for the UltraMist® systems and consumables, which account for more than 98% of total sales.
In addition to the earnings call, SANUWAVE has announced that it will restate its 2024 annual results and the 2024‑2025 interim periods to correct unrecorded state sales and use‑tax obligations. The restatement is expected to increase reported liabilities and expenses, but the company notes that adjusted EBITDA has improved, indicating that the underlying operating performance remains strong despite the tax adjustments.
Revenue growth is driven primarily by the UltraMist® platform, which has maintained high demand across its core segments. Gross margin for Q4 2024 was 77.9%, up from 69.1% in Q4 2023, and the company expects a similar margin profile for Q4 2025. The company’s guidance for the full year reflects confidence in sustaining this margin level while managing the impact of the tax restatement and ongoing market headwinds, such as proposed reimbursement changes for certain wound‑care modalities.
Management emphasized that the company’s sales pipeline remains robust despite regulatory uncertainty. The guidance for Q4 2025 and the full year signals continued confidence in revenue growth and margin maintenance, while the restatement underscores the company’s commitment to accurate financial reporting. Investors can expect the earnings call to provide further detail on these themes and to address any questions regarding the restatement and future outlook.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.